AMF Tjanstepension AB Sells 24,325 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• AMF Tjanstepension AB sharply reduced its IDEXX Laboratories stake in the fourth quarter, selling 24,325 shares and cutting its position by 92.1% to 2,092 shares valued at about $1.4 million.
• IDEXX reported solid quarterly results, with EPS of $3.47 beating estimates and revenue of $1.14 billion topping expectations, while revenue rose 14.3% year over year.
• Analysts remain cautious but generally constructive: the stock has a “Moderate Buy” consensus rating, though several firms recently trimmed price targets, and insider selling has also been notable.

AMF Tjanstepension AB lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 92.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,092 shares of the company's stock after selling 24,325 shares during the quarter. AMF Tjanstepension AB's holdings in IDEXX Laboratories were worth $1,415,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $31,000. Finally, Greykasell Wealth Strategies Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $35,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 3.2%

IDEXX Laboratories stock opened at $545.79 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The business's fifty day simple moving average is $570.62 and its two-hundred day simple moving average is $644.92. IDEXX Laboratories, Inc. has a 12 month low of $496.61 and a 12 month high of $769.98. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 40.19, a price-to-earnings-growth ratio of 3.07 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the company posted $2.91 earnings per share. The company's revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDXX. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 25th. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 28th. Piper Sandler cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. Finally, Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 price target on the stock. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $751.00.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 1,758 shares of the company's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company's stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 27,777 shares of company stock valued at $18,235,113. 0.79% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.